Table 1.
SARS-CoV-2 vaccines granted emergency use listing by WHO
| Vaccine | Manufacturer | Platform | Efficacy on preventing symptomatic infection | Efficacy on preventing severe disease | |
|---|---|---|---|---|---|
| 1 | mRNA-127380 | Moderna | mRNA | 93.2% | 98.2% |
| 2 | BNT162b281 | Pfizer/BioNTech | mRNA | 91.3% | 96.7% |
| 3 | Ad26.COV2.S78 | Janssen | viral vector | 52.4% | 74.6% |
| 4 | AZD122282 | AstraZeneca | viral vector | 74.0% | 100% |
| 5 | Covishield | Serum Institute of India | viral vector | NAa | NA |
| 6 | AD5-nCoV83 | CanSino Biologics | viral vector | 57.5% | 91.7% |
| 7 | BBV15284 | Bharat Biotech | inactivated | 77.8% | 93.4% |
| 8 | BBIBP-CorV85 | Sinopharm | inactivated | 78.1% | 100% |
| 9 | CoronaVac86 | Sinovac | inactivated | 50.7% | 100% |
| 10 | NVX-CoV237287 | Novavax | subunit protein | 89.7% | 100% |
| 11 | COVOVAX | Serum Institute of India | subunit protein | NA | NA |
a
NA, not available.